{ "responseHeader":{ "status":0, "QTime":0, "params":{ "q":"iati_identifier:GB-GOV-10-GAMRIF-C-CAMP", "fl":"*", "format":"json" } }, "response":{ "numFound":1, "start":0, "numFoundExact":true, "docs":[{ "default-currency":"GBP", "default_currency":"GBP", "lang":"en", "default_lang":"en", "iati-identifier":"GB-GOV-10-GAMRIF-C-CAMP", "iati_identifier":"GB-GOV-10-GAMRIF-C-CAMP", "reporting-org.ref":"GB-GOV-10", "reporting_org_ref":"GB-GOV-10", "reporting-org.type":"10", "reporting_org_type_code":"10", "reporting-org.narrative":["UK - Department of Health and Social Care (DHSC)"], "reporting_org_narrative":["UK - Department of Health and Social Care (DHSC)"], "reporting-org.narrative.lang":[" "], "title.narrative":["Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Nurturing breakthrough technologies to solve the global grand challenges of Antimicrobial Resistance (AMR) in the Environment"], "title_narrative":["Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Nurturing breakthrough technologies to solve the global grand challenges of Antimicrobial Resistance (AMR) in the Environment"], "title_narrative_text":["Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Nurturing breakthrough technologies to solve the global grand challenges of Antimicrobial Resistance (AMR) in the Environment"], "title.narrative.lang":[" "], "title_narrative_lang":[" "], "description.narrative":["This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This project is delivered in partnership with the Centre for Cellular and Molecular Platforms (C-CAMP) to nurture promising technologies that can solve the global challenges of AMR in the environment. A national and international call for applications (‘AMR Challenge’) will identify innovative solutions addressing prioritised AMR challenges in the environment for the benefit of LMICs. The Challenge will be specific for AMR in the environment with impact across the One Health* domains of human, animal and the environment. The India AMR Innovation Hub’s large stakeholder network may be leveraged to advance Challenge-funded innovations. (*One Health is an integrated, unifying approach that aims to sustainably balance and optimise the health of people, animals and ecosystems. It recognises that the health of humans, domestic and wild animals, plants, and the wider environment (including ecosystems) are closely linked and interdependent.)"], "description_narrative":["This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This project is delivered in partnership with the Centre for Cellular and Molecular Platforms (C-CAMP) to nurture promising technologies that can solve the global challenges of AMR in the environment. A national and international call for applications (‘AMR Challenge’) will identify innovative solutions addressing prioritised AMR challenges in the environment for the benefit of LMICs. The Challenge will be specific for AMR in the environment with impact across the One Health* domains of human, animal and the environment. The India AMR Innovation Hub’s large stakeholder network may be leveraged to advance Challenge-funded innovations. (*One Health is an integrated, unifying approach that aims to sustainably balance and optimise the health of people, animals and ecosystems. It recognises that the health of humans, domestic and wild animals, plants, and the wider environment (including ecosystems) are closely linked and interdependent.)"], "description_narrative_text":["This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This project is delivered in partnership with the Centre for Cellular and Molecular Platforms (C-CAMP) to nurture promising technologies that can solve the global challenges of AMR in the environment. A national and international call for applications (‘AMR Challenge’) will identify innovative solutions addressing prioritised AMR challenges in the environment for the benefit of LMICs. The Challenge will be specific for AMR in the environment with impact across the One Health* domains of human, animal and the environment. The India AMR Innovation Hub’s large stakeholder network may be leveraged to advance Challenge-funded innovations. (*One Health is an integrated, unifying approach that aims to sustainably balance and optimise the health of people, animals and ecosystems. It recognises that the health of humans, domestic and wild animals, plants, and the wider environment (including ecosystems) are closely linked and interdependent.)"], "description.narrative.lang":[" "], "description_narrative_lang":[" "], "participating-org.ref":["GB-GOV-10","GB-GOV-10","IN-MCA-U73200KA2010NPL052117","IN-MCA-U73200KA2010NPL052117"], "participating_org_ref":["GB-GOV-10","GB-GOV-10","IN-MCA-U73200KA2010NPL052117","IN-MCA-U73200KA2010NPL052117"], "participating-org.role":["1","2","3","4"], "participating_org_role":["1","2","3","4"], "participating-org.type":["10","10","80","80"], "participating_org_type":["10","10","80","80"], "participating-org.narrative":["UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","Centre for Cellular And Mollecular Platforms (C-CAMP)","Centre for Cellular And Mollecular Platforms (C-CAMP)"], "participating_org_narrative":["UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","Centre for Cellular And Mollecular Platforms (C-CAMP)","Centre for Cellular And Mollecular Platforms (C-CAMP)"], "participating_org_narrative_text":["UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","Centre for Cellular And Mollecular Platforms (C-CAMP)","Centre for Cellular And Mollecular Platforms (C-CAMP)"], "participating-org.narrative.lang":[" "," "," "," "], "participating_org_narrative_lang":[" "," "," "," "], "activity-status.code":"2", "activity_status_code":"2", "activity-date.iso-date":["2024-07-22T00:00:00Z","2024-07-22T00:00:00Z","2027-03-31T00:00:00Z"], "activity_date_iso_date":["2024-07-22T00:00:00Z","2024-07-22T00:00:00Z","2027-03-31T00:00:00Z"], "activity-date.type":["1","2","3"], "activity_date_type":["1","2","3"], "contact-info.organisation.narrative":["Department of Health and Social Care (DHSC)"], "contact_info_organisation_narrative":["Department of Health and Social Care (DHSC)"], "contact_info_organisation_narrative_text":["Department of Health and Social Care (DHSC)"], "contact-info.organisation.narrative.lang":[" "], "contact_info_organisation_narrative_lang":[" "], "contact-info.department.narrative":["The UK's Department of Health and Social Care (DHSC) helps people to live more independent, healthier lives for longer. Our official development assistance (ODA) funded programmes take this objective beyond the UK to address global health challenges for the benefit of people living in low- and middle-income countries (LMICs)."], "contact_info_department_narrative":["The UK's Department of Health and Social Care (DHSC) helps people to live more independent, healthier lives for longer. Our official development assistance (ODA) funded programmes take this objective beyond the UK to address global health challenges for the benefit of people living in low- and middle-income countries (LMICs)."], "contact_info_department_narrative_text":["The UK's Department of Health and Social Care (DHSC) helps people to live more independent, healthier lives for longer. Our official development assistance (ODA) funded programmes take this objective beyond the UK to address global health challenges for the benefit of people living in low- and middle-income countries (LMICs)."], "contact-info.department.narrative.lang":[" "], "contact_info_department_narrative_lang":[" "], "contact-info.telephone":["44*(0)*2072104850"], "contact_info_telephone":["44*(0)*2072104850"], "contact-info.mailing-address.narrative":["Department of Health and Social Care, 39 Victoria Street, London, SW1H 0EU, United Kingdom"], "contact_info_mailing_address_narrative":["Department of Health and Social Care, 39 Victoria Street, London, SW1H 0EU, United Kingdom"], "contact_info_mailing_address_narrative_text":["Department of Health and Social Care, 39 Victoria Street, London, SW1H 0EU, United Kingdom"], "contact-info.mailing-address.narrative.lang":[" "], "contact_info_mailing_address_narrative_lang":[" "], "activity-scope.code":"1", "activity_scope_code":"1", "recipient-region.code":["998"], "recipient_region_code":["998"], "recipient-region.percentage":[100.0], "recipient_region_percentage":[100.0], "recipient-region.vocabulary":["1"], "recipient_region_vocabulary":["1"], "sector.code":["12250"], "sector_code":["12250"], "sector.percentage":[100.0], "sector_percentage":[100.0], "sector.vocabulary":["1"], "sector_vocabulary":["1"], "policy-marker.code":["1","2","3","4","5","6","7","8","9","10","11","12"], "policy_marker_code":["1","2","3","4","5","6","7","8","9","10","11","12"], "policy-marker.significance":["0","1","0","0","0","0","1","0","0","1","0","0"], "policy_marker_significance":["0","1","0","0","0","0","1","0","0","1","0","0"], "policy-marker.vocabulary":["1","1","1","1","1","1","1","1","1","1","1","1"], "policy_marker_vocabulary":["1","1","1","1","1","1","1","1","1","1","1","1"], "collaboration-type.code":"1", "collaboration_type_code":"1", "default-flow-type.code":"10", "default_flow_type_code":"10", "default-finance-type.code":"110", "default_finance_type_code":"110", "default-aid-type.code":["C01"], "default_aid_type":["C01"], "default_aid_type_category_code":["C01"], "default_aid_type_code":["C01"], "default-aid-type.vocabulary":["1"], "default_aid_type_vocabulary":["1"], "default-tied-status.code":"5", "default_tied_status_code":"5", "budget.status":["1","1","1","1","1","1"], "budget_status":["1","1","1","1","1","1"], "budget.type":["1","1","1","1","1","1"], "budget_type":["1","1","1","1","1","1"], "budget.period-start.iso-date":["2024-07-22T00:00:00Z","2024-10-01T00:00:00Z","2025-04-01T00:00:00Z","2025-10-01T00:00:00Z","2026-04-01T00:00:00Z","2026-10-01T00:00:00Z"], "budget_period_start_iso_date":["2024-07-22T00:00:00Z","2024-10-01T00:00:00Z","2025-04-01T00:00:00Z","2025-10-01T00:00:00Z","2026-04-01T00:00:00Z","2026-10-01T00:00:00Z"], "budget.period-end.iso-date":["2024-09-30T00:00:00Z","2025-03-31T00:00:00Z","2025-09-30T00:00:00Z","2026-03-31T00:00:00Z","2026-09-30T00:00:00Z","2027-03-31T00:00:00Z"], "budget_period_end_iso_date":["2024-09-30T00:00:00Z","2025-03-31T00:00:00Z","2025-09-30T00:00:00Z","2026-03-31T00:00:00Z","2026-09-30T00:00:00Z","2027-03-31T00:00:00Z"], "budget.value":[525000.0,1575672.0,1574959.0,525000.0,600000.0,299879.0], "budget_value":[525000.0,1575672.0,1574959.0,525000.0,600000.0,299879.0], "budget.value.currency":["GBP","GBP","GBP","GBP","GBP","GBP"], "budget_value_currency":["GBP","GBP","GBP","GBP","GBP","GBP"], "budget.value.value-date":["2024-07-22T00:00:00Z","2024-10-01T00:00:00Z","2025-04-01T00:00:00Z","2025-10-01T00:00:00Z","2026-04-01T00:00:00Z","2026-10-01T00:00:00Z"], "budget_value_date":["2024-07-22T00:00:00Z","2024-10-01T00:00:00Z","2025-04-01T00:00:00Z","2025-10-01T00:00:00Z","2026-04-01T00:00:00Z","2026-10-01T00:00:00Z"], "planned-disbursement.type":["1","1","1","1","1","1"], "planned_disbursement_type":["1","1","1","1","1","1"], "planned-disbursement.period-start.iso-date":["2024-08-06T00:00:00Z","2024-10-01T00:00:00Z","2025-04-01T00:00:00Z","2025-10-01T00:00:00Z","2026-04-01T00:00:00Z","2026-10-01T00:00:00Z"], "planned_disbursement_period_start_iso_date":["2024-08-06T00:00:00Z","2024-10-01T00:00:00Z","2025-04-01T00:00:00Z","2025-10-01T00:00:00Z","2026-04-01T00:00:00Z","2026-10-01T00:00:00Z"], "planned-disbursement.period-end.iso-date":["2024-09-30T00:00:00Z","2025-03-31T00:00:00Z","2025-09-30T00:00:00Z","2026-03-31T00:00:00Z","2026-09-30T00:00:00Z","2027-03-31T00:00:00Z"], "planned_disbursement_period_end_iso_date":["2024-09-30T00:00:00Z","2025-03-31T00:00:00Z","2025-09-30T00:00:00Z","2026-03-31T00:00:00Z","2026-09-30T00:00:00Z","2027-03-31T00:00:00Z"], "planned-disbursement.value":[525000.0,1575672.0,1574959.0,525000.0,600000.0,299879.0], "planned_disbursement_value":[525000.0,1575672.0,1574959.0,525000.0,600000.0,299879.0], "planned-disbursement.provider-org.provider-activity-id":["GB-GOV-10-GAMRIF-C-CAMP","GB-GOV-10-GAMRIF-C-CAMP","GB-GOV-10-GAMRIF-C-CAMP","GB-GOV-10-GAMRIF-C-CAMP","GB-GOV-10-GAMRIF-C-CAMP","GB-GOV-10-GAMRIF-C-CAMP"], "planned_disbursement_provider_org_provider_activity_id":["GB-GOV-10-GAMRIF-C-CAMP","GB-GOV-10-GAMRIF-C-CAMP","GB-GOV-10-GAMRIF-C-CAMP","GB-GOV-10-GAMRIF-C-CAMP","GB-GOV-10-GAMRIF-C-CAMP","GB-GOV-10-GAMRIF-C-CAMP"], "planned-disbursement.provider-org.ref":["GB-GOV-10","GB-GOV-10","GB-GOV-10","GB-GOV-10","GB-GOV-10","GB-GOV-10"], "planned_disbursement_provider_org_ref":["GB-GOV-10","GB-GOV-10","GB-GOV-10","GB-GOV-10","GB-GOV-10","GB-GOV-10"], "planned-disbursement.provider-org.type":["10","10","10","10","10","10"], "planned_disbursement_provider_org_type":["10","10","10","10","10","10"], "planned-disbursement.provider-org.narrative":["UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)"], "planned_disbursement_provider_org_narrative":["UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)"], "planned_disbursement_provider_org_narrative_text":["UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)"], "planned-disbursement.provider-org.narrative.lang":[" "," "," "," "," "," "], "planned_disbursement_provider_org_narrative_lang":[" "," "," "," "," "," "], "planned-disbursement.receiver-org.ref":["IN-MCA-U73200KA2010NPL052117","IN-MCA-U73200KA2010NPL052117","IN-MCA-U73200KA2010NPL052117","IN-MCA-U73200KA2010NPL052117","IN-MCA-U73200KA2010NPL052117","IN-MCA-U73200KA2010NPL052117"], "planned_disbursement_receiver_org_ref":["IN-MCA-U73200KA2010NPL052117","IN-MCA-U73200KA2010NPL052117","IN-MCA-U73200KA2010NPL052117","IN-MCA-U73200KA2010NPL052117","IN-MCA-U73200KA2010NPL052117","IN-MCA-U73200KA2010NPL052117"], "planned-disbursement.receiver-org.type":["80","80","80","80","80","80"], "planned_disbursement_receiver_org_type":["80","80","80","80","80","80"], "planned-disbursement.receiver-org.narrative":["Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)"], "planned_disbursement_receiver_org_narrative":["Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)"], "planned_disbursement_receiver_org_narrative_text":["Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)"], "planned-disbursement.receiver-org.narrative.lang":[" "," "," "," "," "," "], "planned_disbursement_receiver_org_narrative_lang":[" "," "," "," "," "," "], "planned-disbursement.value.currency":["GBP","GBP","GBP","GBP","GBP","GBP"], "planned_disbursement_value_currency":["GBP","GBP","GBP","GBP","GBP","GBP"], "planned-disbursement.value.value-date":["2024-08-06T00:00:00Z","2024-10-01T00:00:00Z","2025-04-01T00:00:00Z","2025-10-01T00:00:00Z","2026-04-01T00:00:00Z","2026-10-01T00:00:00Z"], "planned_disbursement_value_date":["2024-08-06T00:00:00Z","2024-10-01T00:00:00Z","2025-04-01T00:00:00Z","2025-10-01T00:00:00Z","2026-04-01T00:00:00Z","2026-10-01T00:00:00Z"], "capital-spend.percentage":100.0, "capital_spend_percentage":100.0, "transaction.humanitarian":[false,false,false,false], "transaction_humanitarian":["0","0","0","0"], "transaction.transaction-type.code":["3","3","3","2"], "transaction_type":["3","3","3","2"], "transaction.transaction-date.iso-date":["2026-01-26T00:00:00Z","2024-12-06T00:00:00Z","2024-08-23T00:00:00Z","2024-07-22T00:00:00Z"], "transaction_date_iso_date":["2026-01-26T00:00:00Z","2024-12-06T00:00:00Z","2024-08-23T00:00:00Z","2024-07-22T00:00:00Z"], "transaction.value":[2099959.0,1575672.0,525000.0,5100510.0], "transaction_value":[2099959.0,1575672.0,525000.0,5100510.0], "transaction.provider-org.provider-activity-id":["GB-GOV-10-GAMRIF-C-CAMP","GB-GOV-10-GAMRIF-C-CAMP","GB-GOV-10-GAMRIF-C-CAMP","GB-GOV-10-GAMRIF-C-CAMP"], "transaction_provider_org_provider_activity_id":["GB-GOV-10-GAMRIF-C-CAMP","GB-GOV-10-GAMRIF-C-CAMP","GB-GOV-10-GAMRIF-C-CAMP","GB-GOV-10-GAMRIF-C-CAMP"], "transaction.provider-org.ref":["GB-GOV-10","GB-GOV-10","GB-GOV-10","GB-GOV-10"], "transaction_provider_org_ref":["GB-GOV-10","GB-GOV-10","GB-GOV-10","GB-GOV-10"], "transaction.provider-org.type":["10","10","10","10"], "transaction_provider_org_type":["10","10","10","10"], "transaction.provider-org.narrative":["UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)"], "transaction_provider_org_narrative":["UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)"], "transaction_provider_org_narrative_text":["UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)"], "transaction.provider-org.narrative.lang":[" "," "," "," "], "transaction_provider_org_narrative_lang":[" "," "," "," "], "transaction.receiver-org.ref":["IN-MCA-U73200KA2010NPL052117","IN-MCA-U73200KA2010NPL052117","IN-MCA-U73200KA2010NPL052117","IN-MCA-U73200KA2010NPL052117"], "transaction_receiver_org_ref":["IN-MCA-U73200KA2010NPL052117","IN-MCA-U73200KA2010NPL052117","IN-MCA-U73200KA2010NPL052117","IN-MCA-U73200KA2010NPL052117"], "transaction.receiver-org.type":["80","80","80","80"], "transaction_receiver_org_type_code":["80","80","80","80"], "transaction.receiver-org.narrative":["Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)"], "transaction_receiver_org_narrative":["Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)"], "transaction_receiver_org_narrative_text":["Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)","Centre for Cellular and Molecular Platforms (C-CAMP)"], "transaction.receiver-org.narrative.lang":[" "," "," "," "], "transaction_receiver_org_narrative_lang":[" "," "," "," "], "transaction.flow-type.code":["10","10","10","10"], "transaction_flow_type_code":["10","10","10","10"], "transaction.finance-type.code":["110","110","110","110"], "transaction_finance_type_code":["110","110","110","110"], "transaction.aid-type.code":["C01","C01","C01","C01"], "transaction_aid_type_code":["C01","C01","C01","C01"], "transaction.aid-type.vocabulary":["1","1","1","1"], "transaction_aid_type_vocabulary":["1","1","1","1"], "transaction.tied-status.code":["5","5","5","5"], "transaction_tied_status_code":["5","5","5","5"], "transaction.value.currency":["GBP","GBP","GBP","GBP"], "transaction_value_currency":["GBP","GBP","GBP","GBP"], "transaction.value.value-date":["2026-01-26T00:00:00Z","2024-12-06T00:00:00Z","2024-08-23T00:00:00Z","2024-07-22T00:00:00Z"], "transaction_value_date":["2026-01-26T00:00:00Z","2024-12-06T00:00:00Z","2024-08-23T00:00:00Z","2024-07-22T00:00:00Z"], "transaction.description.narrative":["GAMRIF Phase 2 C-CAMP Grant Agreement"], "transaction_description_narrative":["GAMRIF Phase 2 C-CAMP Grant Agreement"], "transaction.description.narrative.lang":[" "], "transaction_description_lang":[" "], "document-link.format":["application/pdf"], "document_link_format":["application/pdf"], "document-link.url":["https://drive.google.com/file/d/1EelaTSrWnqcyahPCn0izgacqZt4YE-2q/view?usp=drive_link"], "document_link_url":["https://drive.google.com/file/d/1EelaTSrWnqcyahPCn0izgacqZt4YE-2q/view?usp=drive_link"], "document-link.title.narrative":["GAMRIF - C-CAMP - Grant Agreement - 2024"], "document_link_title_narrative":["GAMRIF - C-CAMP - Grant Agreement - 2024"], "document_link_title_narrative_text":["GAMRIF - C-CAMP - Grant Agreement - 2024"], "document-link.title.narrative.lang":[" "], "document_link_title_narrative_lang":[" "], "document-link.category.code":["A02","A03","A04","A05","A11"], "document_link_category_code":["A02","A03","A04","A05","A11"], "document-link.document-date.iso-date":["2024-07-22T00:00:00Z"], "document_link_document_date_iso_date":["2024-07-22T00:00:00Z"], "related-activity.ref":["GB-GOV-10-GAMRIF","GB-GOV-10-GAMRIF-BACTIVAC","GB-GOV-10-GAMRIF-CHAI","GB-GOV-10-GAMRIF-ICARS","GB-GOV-10-GAMRIF-ProgrammeCosts","GB-GOV-10-GAMRIF-WP11-CMM","GB-GOV-10-GAMRIF-WP12-MHRA","GB-GOV-10-GAMRIF-WP1-UK-CHINA","GB-GOV-10-GAMRIF-WP2-CARB-X","GB-GOV-10-GAMRIF-WP3-InnoVet-AMR","GB-GOV-10-GAMRIF-WP4-UK-Argentina","GB-GOV-10-GAMRIF-WP5-FIND","GB-GOV-10-GAMRIF-WP6-GARDP","GB-GOV-10-GAMRIF-WP6-GARDP-2","GB-GOV-10-GAMRIF-WP6-GARDP-2019-2022","GB-GOV-10-GAMRIF-WP6-GARDP-3","GB-GOV-10-GAMRIF-WP6-GARDP-CORE"], "related_activity_ref":["GB-GOV-10-GAMRIF","GB-GOV-10-GAMRIF-BACTIVAC","GB-GOV-10-GAMRIF-CHAI","GB-GOV-10-GAMRIF-ICARS","GB-GOV-10-GAMRIF-ProgrammeCosts","GB-GOV-10-GAMRIF-WP11-CMM","GB-GOV-10-GAMRIF-WP12-MHRA","GB-GOV-10-GAMRIF-WP1-UK-CHINA","GB-GOV-10-GAMRIF-WP2-CARB-X","GB-GOV-10-GAMRIF-WP3-InnoVet-AMR","GB-GOV-10-GAMRIF-WP4-UK-Argentina","GB-GOV-10-GAMRIF-WP5-FIND","GB-GOV-10-GAMRIF-WP6-GARDP","GB-GOV-10-GAMRIF-WP6-GARDP-2","GB-GOV-10-GAMRIF-WP6-GARDP-2019-2022","GB-GOV-10-GAMRIF-WP6-GARDP-3","GB-GOV-10-GAMRIF-WP6-GARDP-CORE"], "related-activity.type":["1","3","3","3","3","3","3","3","3","3","3","3","3","3","3","3","3"], "related_activity_type":["1","3","3","3","3","3","3","3","3","3","3","3","3","3","3","3","3"], "conditions.attached":true, "conditions_attached":"1", "conditions.condition.type":["2"], "conditions_condition_type":["2"], "conditions.condition.narrative":["Payments will be released on receipt of confirmation that the Grant already disbursed has been spent and provided the Funded Activities have been delivered during the previous period."], "conditions_condition_narrative":["Payments will be released on receipt of confirmation that the Grant already disbursed has been spent and provided the Funded Activities have been delivered during the previous period."], "conditions_condition_narrative_text":["Payments will be released on receipt of confirmation that the Grant already disbursed has been spent and provided the Funded Activities have been delivered during the previous period."], "conditions.condition.narrative.lang":[" "], "conditions_condition_narrative_lang":[" "], "reporting-org.type.name":"Government", "reporting_org_type_name":"Government", "recipient-region.name":["Developing countries, unspecified"], "recipient_region_name":["Developing countries, unspecified"], "default-aid-type.name":["Project-type interventions"], "default_aid_type_category_name":["Project-type interventions"], "policy-marker.name":["Gender Equality","Aid to Environment","Participatory Development/Good Governance","Trade Development","Aid Targeting the Objectives of the Convention on Biological Diversity","Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation","Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation","Aid Targeting the Objectives of the Convention to Combat Desertification","Reproductive, Maternal, Newborn and Child Health (RMNCH)","Disaster Risk Reduction(DRR)","Disability","Nutrition"], "policy-marker.significance.name":["not targeted","significant objective","not targeted","not targeted","not targeted","not targeted","significant objective","not targeted","not targeted","significant objective","not targeted","not targeted"], "policy-marker.vocabulary.name":["OECD DAC CRS","OECD DAC CRS","OECD DAC CRS","OECD DAC CRS","OECD DAC CRS","OECD DAC CRS","OECD DAC CRS","OECD DAC CRS","OECD DAC CRS","OECD DAC CRS","OECD DAC CRS","OECD DAC CRS"], "budget.type.name":["Original","Original","Original","Original","Original","Original"], "budget.status.name":["Indicative","Indicative","Indicative","Indicative","Indicative","Indicative"], "transaction.receiver-org.type.name":["Academic, Training and Research","Academic, Training and Research","Academic, Training and Research","Academic, Training and Research"], "transaction_receiver_org_type_name":["Academic, Training and Research","Academic, Training and Research","Academic, Training and Research","Academic, Training and Research"], "title.narrative.first":"Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Nurturing breakthrough technologies to solve the global grand challenges of Antimicrobial Resistance (AMR) in the Environment", "title_narrative_first":"Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Nurturing breakthrough technologies to solve the global grand challenges of Antimicrobial Resistance (AMR) in the Environment", "activity-date.start-planned":"2024-07-22T00:00:00Z", "activity_date_start_planned":"Mon Jul 22 00:00:00 UTC 2024", "activity_date_start_planned_f":"2024-07-22T00:00:00Z", "activity-date.common.start":"2024-07-22T00:00:00Z", "activity_date_start_common":"Mon Jul 22 00:00:00 UTC 2024", "activity_date_start_common_f":"2024-07-22T00:00:00Z", "activity-date.start-actual":"2024-07-22T00:00:00Z", "activity_date_start_actual":"Mon Jul 22 00:00:00 UTC 2024", "activity_date_start_actual_f":"2024-07-22T00:00:00Z", "activity-date.end-planned":"2027-03-31T00:00:00Z", "activity_date_end_planned":"Wed Mar 31 00:00:00 UTC 2027", "activity_date_end_planned_f":"2027-03-31T00:00:00Z", "activity-date.common.end":"2027-03-31T00:00:00Z", "activity_date_end_common":"Wed Mar 31 00:00:00 UTC 2027", "activity_date_end_common_f":"2027-03-31T00:00:00Z", "activity-status.text":"Implementation", "activity_status_text":"Implementation", "policy-marker.combined":["1__0","2__1","3__0","4__0","5__0","6__0","7__1","8__0","9__0","10__1","11__0","12__0"], "policy_marker_combined":["1__0","2__1","3__0","4__0","5__0","6__0","7__1","8__0","9__0","10__1","11__0","12__0"], "budget.value-usd":[665358.6267638084,2099505.047361555,2033194.0339654996,707148.9092165444,798090.0911714799,398884.09741735365], "budget_value_usd":[665358.6267638084,2099505.047361555,2033194.0339654996,707148.9092165444,798090.0911714799,398884.09741735365], "budget.value-usd.sum":6702180.805896241, "budget_value_usd_sum":6702180.805896241, "budget.value-usd.conversion-rate":[0.7890481597172807,0.750496885911346,0.7746230677886815,0.7424178884496216,0.7517948244656033,0.7517948244656033], "budget_usd_conversion_rate":[0.7890481597172807,0.750496885911346,0.7746230677886815,0.7424178884496216,0.7517948244656033,0.7517948244656033], "budget.value-usd.conversion-currency":["GBP"], "budget.value-gbp":[525000.0,1575672.0,1574959.0,525000.0,600000.0,299879.0], "budget_value_gbp":[525000.0,1575672.0,1574959.0,525000.0,600000.0,299879.0], "budget.value-gbp.sum":5100510.0, "budget_value_gbp_sum":5100510.0, "budget.value-gbp.conversion-rate":[1.0,1.0,1.0,1.0,1.0,1.0], "budget_gbp_conversion_rate":[1.0,1.0,1.0,1.0,1.0,1.0], "budget.value-gbp.conversion-currency":["GBP"], "planned-disbursement.value-usd":[670451.3125694331,2099505.047361555,2033194.0339654996,707148.9092165444,798090.0911714799,398884.09741735365], "planned_disbursement_value_usd":[670451.3125694331,2099505.047361555,2033194.0339654996,707148.9092165444,798090.0911714799,398884.09741735365], "planned-disbursement.value-usd.sum":6707273.4917018665, "planned_disbursement_value_usd_sum":6707273.4917018665, "planned-disbursement.value-usd.conversion-rate":[0.7830546232924707,0.750496885911346,0.7746230677886815,0.7424178884496216,0.7517948244656033,0.7517948244656033], "planned_disbursement_usd_conversion_rate":[0.7830546232924707,0.750496885911346,0.7746230677886815,0.7424178884496216,0.7517948244656033,0.7517948244656033], "planned-disbursement.value-usd.conversion-currency":["GBP"], "planned-disbursement.value-gbp":[525000.0,1575672.0,1574959.0,525000.0,600000.0,299879.0], "planned_disbursement_value_gbp":[525000.0,1575672.0,1574959.0,525000.0,600000.0,299879.0], "planned-disbursement.value-gbp.sum":5100510.0, "planned_disbursement_value_gbp_sum":5100510.0, "planned-disbursement.value-gbp.conversion-rate":[1.0,1.0,1.0,1.0,1.0,1.0], "planned_disbursement_gbp_conversion_rate":[1.0,1.0,1.0,1.0,1.0,1.0], "planned-disbursement.value-gbp.conversion-currency":["GBP"], "transaction.value-usd.sum":1.1959159065018713E7, "transaction_value_usd_sum":1.1959159065018713E7, "transaction.value-usd.conversion-rate":[0.7441861175607968,0.7867510842683089,0.7830546232924707,0.7890481597172807], "transaction_usd_conversion_rate":[0.7441861175607968,0.7867510842683089,0.7830546232924707,0.7890481597172807], "transaction.value-usd.conversion-currency":["GBP"], "transaction.value-gbp.sum":9301141.0, "transaction_value_gbp_sum":9301141.0, "transaction.value-gbp.conversion-rate":[1.0,1.0,1.0,1.0], "transaction_gbp_conversion_rate":[1.0,1.0,1.0,1.0], "transaction.value-gbp.conversion-currency":["GBP"], "dataset.id":"80b95c71-d3ca-4a37-aa4b-892f57c35440", "dataset_iati_id":"80b95c71-d3ca-4a37-aa4b-892f57c35440", "dataset.name":"dhsc-activities-ghs", "dataset_name":"dhsc-activities-ghs", "dataset.extras.iati_version":"2.03", "dataset.resources.hash":"6226d602bc8a174d77ae73beb0d63d098527fc59", "dataset.resources.url":"https://dhsc-govuk.github.io/iati-oda-spending-metadata/dhsc-activities-ghs.xml", "hierarchy":1, "activity-date.quarter":[3,3,1], "budget.period-start.quarter":[3,4,2,4,2,4], "budget.period-end.quarter":[3,1,3,1,3,1], "planned-disbursement.period-start.quarter":[3,4,2,4,2,4], "planned-disbursement.period-end.quarter":[3,1,3,1,3,1], "transaction.transaction-date.quarter":[1,4,3,3], "document-link.document-date.quarter":[3], "document-link.category-codes-combined":["A02,A03,A04,A05,A11"], "transaction.value-usd":[2821819.636844331,2002757.9643762426,670451.3125694331,6464130.151228708], "transaction_value_usd":[2821819.636844331,2002757.9643762426,670451.3125694331,6464130.151228708], "transaction.value-usd-type":[3,3,3,2], "transaction.value-gbp":[2099959.0,1575672.0,525000.0,5100510.0], "transaction_value_gbp":[2099959.0,1575672.0,525000.0,5100510.0], "transaction.value-gbp-type":[3,3,3,2], "activity-aggregation.budget.value":5100510.0, "activity_aggregation_budget_value":5100510.0, "activity-aggregation.budget.value-usd":6702180.805896241, "activity_aggregation_budget_value_usd":6702180.805896241, "activity-aggregation.budget.value-gbp":5100510.0, "activity_aggregation_budget_value_gbp":5100510.0, "activity-aggregation.budget.currency":"GBP", "activity_aggregation_budget_currency":"GBP", "activity-aggregation.planned-disbursement.value":5100510.0, "activity-aggregation.planned-disbursement.value-usd":6707273.4917018665, "activity-aggregation.planned-disbursement.value-gbp":5100510.0, "activity-aggregation.planned-disbursement.currency":"GBP", "activity-aggregation.outgoing-commitment.value":5100510.0, "activity_aggregation_commitment_value":5100510.0, "activity-aggregation.outgoing-commitment.value-usd":6464130.151228708, "activity_aggregation_commitment_value_usd":6464130.151228708, "activity-aggregation.outgoing-commitment.value-gbp":5100510.0, "activity_aggregation_commitment_value_gbp":5100510.0, "activity-aggregation.disbursement.value":4200631.0, "activity_aggregation_disbursement_value":4200631.0, "activity-aggregation.disbursement.value-usd":5495028.913790006, "activity_aggregation_disbursement_value_usd":5495028.913790006, "activity-aggregation.disbursement.value-gbp":4200631.0, "activity_aggregation_disbursement_value_gbp":4200631.0, "json.reporting-org":"{\"ref\": \"GB-GOV-10\", \"type\": 10, \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}", "json.title":"{\"narrative\": \"Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Nurturing breakthrough technologies to solve the global grand challenges of Antimicrobial Resistance (AMR) in the Environment\", \"narrative.lang\": \" \"}", "json.description":["{\"narrative\": \"This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)\\u2019s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This project is delivered in partnership with the Centre for Cellular and Molecular Platforms (C-CAMP) to nurture promising technologies that can solve the global challenges of AMR in the environment. A national and international call for applications (\\u2018AMR Challenge\\u2019) will identify innovative solutions addressing prioritised AMR challenges in the environment for the benefit of LMICs. The Challenge will be specific for AMR in the environment with impact across the One Health* domains of human, animal and the environment. The India AMR Innovation Hub\\u2019s large stakeholder network may be leveraged to advance Challenge-funded innovations. (*One Health is an integrated, unifying approach that aims to sustainably balance and optimise the health of people, animals and ecosystems. It recognises that the health of humans, domestic and wild animals, plants, and the wider environment (including ecosystems) are closely linked and interdependent.)\", \"narrative.lang\": \" \"}"], "json.participating-org":["{\"ref\": \"GB-GOV-10\", \"role\": 1, \"type\": 10, \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}","{\"ref\": \"GB-GOV-10\", \"role\": 2, \"type\": 10, \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}","{\"ref\": \"IN-MCA-U73200KA2010NPL052117\", \"role\": 3, \"type\": 80, \"narrative\": \"Centre for Cellular And Mollecular Platforms (C-CAMP)\", \"narrative.lang\": \" \"}","{\"ref\": \"IN-MCA-U73200KA2010NPL052117\", \"role\": 4, \"type\": 80, \"narrative\": \"Centre for Cellular And Mollecular Platforms (C-CAMP)\", \"narrative.lang\": \" \"}"], "json.activity-date":["{\"iso-date\": \"2024-07-22\", \"type\": 1}","{\"iso-date\": \"2024-07-22\", \"type\": 2}","{\"iso-date\": \"2027-03-31\", \"type\": 3}"], "json.contact-info":["{\"organisation\": {\"narrative\": \"Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}, \"department\": {\"narrative\": \"The UK's Department of Health and Social Care (DHSC) helps people to live more independent, healthier lives for longer. Our official development assistance (ODA) funded programmes take this objective beyond the UK to address global health challenges for the benefit of people living in low- and middle-income countries (LMICs).\", \"narrative.lang\": \" \"}, \"telephone\": \"44*(0)*2072104850\", \"mailing-address\": {\"narrative\": \"Department of Health and Social Care, 39 Victoria Street, London, SW1H 0EU, United Kingdom\", \"narrative.lang\": \" \"}}"], "json.recipient-region":["{\"code\": 998, \"percentage\": 100, \"vocabulary\": 1}"], "json.sector":["{\"code\": 12250, \"percentage\": 100, \"vocabulary\": 1}"], "json.policy-marker":["{\"code\": 1, \"significance\": 0, \"vocabulary\": 1}","{\"code\": 2, \"significance\": 1, \"vocabulary\": 1}","{\"code\": 3, \"significance\": 0, \"vocabulary\": 1}","{\"code\": 4, \"significance\": 0, \"vocabulary\": 1}","{\"code\": 5, \"significance\": 0, \"vocabulary\": 1}","{\"code\": 6, \"significance\": 0, \"vocabulary\": 1}","{\"code\": 7, \"significance\": 1, \"vocabulary\": 1}","{\"code\": 8, \"significance\": 0, \"vocabulary\": 1}","{\"code\": 9, \"significance\": 0, \"vocabulary\": 1}","{\"code\": 10, \"significance\": 1, \"vocabulary\": 1}","{\"code\": 11, \"significance\": 0, \"vocabulary\": 1}","{\"code\": 12, \"significance\": 0, \"vocabulary\": 1}"], "json.default-aid-type":["{\"code\": \"C01\", \"vocabulary\": 1}"], "json.budget":["{\"status\": 1, \"type\": 1, \"period-start\": [{\"iso-date\": \"2024-07-22\"}], \"period-end\": [{\"iso-date\": \"2024-09-30\"}], \"value\": 525000, \"value.currency\": \"GBP\", \"value.value-date\": \"2024-07-22\"}","{\"status\": 1, \"type\": 1, \"period-start\": [{\"iso-date\": \"2024-10-01\"}], \"period-end\": [{\"iso-date\": \"2025-03-31\"}], \"value\": 1575672, \"value.currency\": \"GBP\", \"value.value-date\": \"2024-10-01\"}","{\"status\": 1, \"type\": 1, \"period-start\": [{\"iso-date\": \"2025-04-01\"}], \"period-end\": [{\"iso-date\": \"2025-09-30\"}], \"value\": 1574959, \"value.currency\": \"GBP\", \"value.value-date\": \"2025-04-01\"}","{\"status\": 1, \"type\": 1, \"period-start\": [{\"iso-date\": \"2025-10-01\"}], \"period-end\": [{\"iso-date\": \"2026-03-31\"}], \"value\": 525000, \"value.currency\": \"GBP\", \"value.value-date\": \"2025-10-01\"}","{\"status\": 1, \"type\": 1, \"period-start\": [{\"iso-date\": \"2026-04-01\"}], \"period-end\": [{\"iso-date\": \"2026-09-30\"}], \"value\": 600000, \"value.currency\": \"GBP\", \"value.value-date\": \"2026-04-01\"}","{\"status\": 1, \"type\": 1, \"period-start\": [{\"iso-date\": \"2026-10-01\"}], \"period-end\": [{\"iso-date\": \"2027-03-31\"}], \"value\": 299879, \"value.currency\": \"GBP\", \"value.value-date\": \"2026-10-01\"}"], "json.planned-disbursement":["{\"type\": 1, \"period-start\": [{\"iso-date\": \"2024-08-06\"}], \"period-end\": [{\"iso-date\": \"2024-09-30\"}], \"value\": 525000, \"provider-org\": {\"provider-activity-id\": \"GB-GOV-10-GAMRIF-C-CAMP\", \"ref\": \"GB-GOV-10\", \"type\": 10, \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}, \"receiver-org\": {\"ref\": \"IN-MCA-U73200KA2010NPL052117\", \"type\": 80, \"narrative\": \"Centre for Cellular and Molecular Platforms (C-CAMP)\", \"narrative.lang\": \" \"}, \"value.currency\": \"GBP\", \"value.value-date\": \"2024-08-06\"}","{\"type\": 1, \"period-start\": [{\"iso-date\": \"2024-10-01\"}], \"period-end\": [{\"iso-date\": \"2025-03-31\"}], \"value\": 1575672, \"provider-org\": {\"provider-activity-id\": \"GB-GOV-10-GAMRIF-C-CAMP\", \"ref\": \"GB-GOV-10\", \"type\": 10, \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}, \"receiver-org\": {\"ref\": \"IN-MCA-U73200KA2010NPL052117\", \"type\": 80, \"narrative\": \"Centre for Cellular and Molecular Platforms (C-CAMP)\", \"narrative.lang\": \" \"}, \"value.currency\": \"GBP\", \"value.value-date\": \"2024-10-01\"}","{\"type\": 1, \"period-start\": [{\"iso-date\": \"2025-04-01\"}], \"period-end\": [{\"iso-date\": \"2025-09-30\"}], \"value\": 1574959, \"provider-org\": {\"provider-activity-id\": \"GB-GOV-10-GAMRIF-C-CAMP\", \"ref\": \"GB-GOV-10\", \"type\": 10, \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}, \"receiver-org\": {\"ref\": \"IN-MCA-U73200KA2010NPL052117\", \"type\": 80, \"narrative\": \"Centre for Cellular and Molecular Platforms (C-CAMP)\", \"narrative.lang\": \" \"}, \"value.currency\": \"GBP\", \"value.value-date\": \"2025-04-01\"}","{\"type\": 1, \"period-start\": [{\"iso-date\": \"2025-10-01\"}], \"period-end\": [{\"iso-date\": \"2026-03-31\"}], \"value\": 525000, \"provider-org\": {\"provider-activity-id\": \"GB-GOV-10-GAMRIF-C-CAMP\", \"ref\": \"GB-GOV-10\", \"type\": 10, \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}, \"receiver-org\": {\"ref\": \"IN-MCA-U73200KA2010NPL052117\", \"type\": 80, \"narrative\": \"Centre for Cellular and Molecular Platforms (C-CAMP)\", \"narrative.lang\": \" \"}, \"value.currency\": \"GBP\", \"value.value-date\": \"2025-10-01\"}","{\"type\": 1, \"period-start\": [{\"iso-date\": \"2026-04-01\"}], \"period-end\": [{\"iso-date\": \"2026-09-30\"}], \"value\": 600000, \"provider-org\": {\"provider-activity-id\": \"GB-GOV-10-GAMRIF-C-CAMP\", \"ref\": \"GB-GOV-10\", \"type\": 10, \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}, \"receiver-org\": {\"ref\": \"IN-MCA-U73200KA2010NPL052117\", \"type\": 80, \"narrative\": \"Centre for Cellular and Molecular Platforms (C-CAMP)\", \"narrative.lang\": \" \"}, \"value.currency\": \"GBP\", \"value.value-date\": \"2026-04-01\"}","{\"type\": 1, \"period-start\": [{\"iso-date\": \"2026-10-01\"}], \"period-end\": [{\"iso-date\": \"2027-03-31\"}], \"value\": 299879, \"provider-org\": {\"provider-activity-id\": \"GB-GOV-10-GAMRIF-C-CAMP\", \"ref\": \"GB-GOV-10\", \"type\": 10, \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}, \"receiver-org\": {\"ref\": \"IN-MCA-U73200KA2010NPL052117\", \"type\": 80, \"narrative\": \"Centre for Cellular and Molecular Platforms (C-CAMP)\", \"narrative.lang\": \" \"}, \"value.currency\": \"GBP\", \"value.value-date\": \"2026-10-01\"}"], "json.transaction":["{\"humanitarian\": 0, \"transaction-type\": {\"code\": 3}, \"transaction-date\": {\"iso-date\": \"2026-01-26\"}, \"value\": 2099959, \"provider-org\": {\"provider-activity-id\": \"GB-GOV-10-GAMRIF-C-CAMP\", \"ref\": \"GB-GOV-10\", \"type\": 10, \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}, \"receiver-org\": {\"ref\": \"IN-MCA-U73200KA2010NPL052117\", \"type\": 80, \"narrative\": \"Centre for Cellular and Molecular Platforms (C-CAMP)\", \"narrative.lang\": \" \"}, \"flow-type\": {\"code\": 10}, \"finance-type\": {\"code\": 110}, \"aid-type\": {\"code\": \"C01\", \"vocabulary\": 1}, \"tied-status\": {\"code\": 5}, \"value.currency\": \"GBP\", \"value.value-date\": \"2026-01-26\"}","{\"humanitarian\": 0, \"transaction-type\": {\"code\": 3}, \"transaction-date\": {\"iso-date\": \"2024-12-06\"}, \"value\": 1575672, \"provider-org\": {\"provider-activity-id\": \"GB-GOV-10-GAMRIF-C-CAMP\", \"ref\": \"GB-GOV-10\", \"type\": 10, \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}, \"receiver-org\": {\"ref\": \"IN-MCA-U73200KA2010NPL052117\", \"type\": 80, \"narrative\": \"Centre for Cellular and Molecular Platforms (C-CAMP)\", \"narrative.lang\": \" \"}, \"flow-type\": {\"code\": 10}, \"finance-type\": {\"code\": 110}, \"aid-type\": {\"code\": \"C01\", \"vocabulary\": 1}, \"tied-status\": {\"code\": 5}, \"value.currency\": \"GBP\", \"value.value-date\": \"2024-12-06\"}","{\"humanitarian\": 0, \"transaction-type\": {\"code\": 3}, \"transaction-date\": {\"iso-date\": \"2024-08-23\"}, \"value\": 525000, \"provider-org\": {\"provider-activity-id\": \"GB-GOV-10-GAMRIF-C-CAMP\", \"ref\": \"GB-GOV-10\", \"type\": 10, \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}, \"receiver-org\": {\"ref\": \"IN-MCA-U73200KA2010NPL052117\", \"type\": 80, \"narrative\": \"Centre for Cellular and Molecular Platforms (C-CAMP)\", \"narrative.lang\": \" \"}, \"flow-type\": {\"code\": 10}, \"finance-type\": {\"code\": 110}, \"aid-type\": {\"code\": \"C01\", \"vocabulary\": 1}, \"tied-status\": {\"code\": 5}, \"value.currency\": \"GBP\", \"value.value-date\": \"2024-08-23\"}","{\"humanitarian\": 0, \"transaction-type\": {\"code\": 2}, \"transaction-date\": {\"iso-date\": \"2024-07-22\"}, \"value\": 5100510, \"description\": {\"narrative\": \"GAMRIF Phase 2 C-CAMP Grant Agreement\", \"narrative.lang\": \" \"}, \"provider-org\": {\"provider-activity-id\": \"GB-GOV-10-GAMRIF-C-CAMP\", \"ref\": \"GB-GOV-10\", \"type\": 10, \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}, \"receiver-org\": {\"ref\": \"IN-MCA-U73200KA2010NPL052117\", \"type\": 80, \"narrative\": \"Centre for Cellular and Molecular Platforms (C-CAMP)\", \"narrative.lang\": \" \"}, \"flow-type\": {\"code\": 10}, \"finance-type\": {\"code\": 110}, \"aid-type\": {\"code\": \"C01\", \"vocabulary\": 1}, \"tied-status\": {\"code\": 5}, \"value.currency\": \"GBP\", \"value.value-date\": \"2024-07-22\"}"], "json.document-link":["{\"format\": \"application/pdf\", \"url\": \"https://drive.google.com/file/d/1EelaTSrWnqcyahPCn0izgacqZt4YE-2q/view?usp=drive_link\", \"title\": {\"narrative\": \"GAMRIF - C-CAMP - Grant Agreement - 2024\", \"narrative.lang\": \" \"}, \"category\": [{\"code\": \"A02\"}, {\"code\": \"A03\"}, {\"code\": \"A04\"}, {\"code\": \"A05\"}, {\"code\": \"A11\"}], \"document-date\": [{\"iso-date\": \"2024-07-22\"}]}"], "json.related-activity":["{\"ref\": \"GB-GOV-10-GAMRIF\", \"type\": 1}","{\"ref\": \"GB-GOV-10-GAMRIF-BACTIVAC\", \"type\": 3}","{\"ref\": \"GB-GOV-10-GAMRIF-CHAI\", \"type\": 3}","{\"ref\": \"GB-GOV-10-GAMRIF-ICARS\", \"type\": 3}","{\"ref\": \"GB-GOV-10-GAMRIF-ProgrammeCosts\", \"type\": 3}","{\"ref\": \"GB-GOV-10-GAMRIF-WP11-CMM\", \"type\": 3}","{\"ref\": \"GB-GOV-10-GAMRIF-WP12-MHRA\", \"type\": 3}","{\"ref\": \"GB-GOV-10-GAMRIF-WP1-UK-CHINA\", \"type\": 3}","{\"ref\": \"GB-GOV-10-GAMRIF-WP2-CARB-X\", \"type\": 3}","{\"ref\": \"GB-GOV-10-GAMRIF-WP3-InnoVet-AMR\", \"type\": 3}","{\"ref\": \"GB-GOV-10-GAMRIF-WP4-UK-Argentina\", \"type\": 3}","{\"ref\": \"GB-GOV-10-GAMRIF-WP5-FIND\", \"type\": 3}","{\"ref\": \"GB-GOV-10-GAMRIF-WP6-GARDP\", \"type\": 3}","{\"ref\": \"GB-GOV-10-GAMRIF-WP6-GARDP-2\", \"type\": 3}","{\"ref\": \"GB-GOV-10-GAMRIF-WP6-GARDP-2019-2022\", \"type\": 3}","{\"ref\": \"GB-GOV-10-GAMRIF-WP6-GARDP-3\", \"type\": 3}","{\"ref\": \"GB-GOV-10-GAMRIF-WP6-GARDP-CORE\", \"type\": 3}"], "json.conditions":"{\"attached\": 1, \"condition\": {\"type\": 2, \"narrative\": \"Payments will be released on receipt of confirmation that the Grant already disbursed has been spent and provided the Funded Activities have been delivered during the previous period.\", \"narrative.lang\": \" \"}}", "related_budget_value":[1000000,0,4000000,15000000,19890000,15000000,12900000,16300000,27700000,23500000,250000,150000,350000,150000,100000,200000,118000,82000,348955,198474,353987,277415,221130,390446,254961,25878,25878,0,0,21793,7878,6510,152463,69663,34096,296545,300000,16915,32000,75000,804955,441085,444000,179000,408005,169000,290296,243000,245000,122000,702670,544457,548243,0,0,68737,31920,362302,15499,2873514,2890457,3533253,766281,125000,125000,125000,625000,1625000,1625000,1625000,1625000,1625000,1625000,1625000,1625000,1500000,1500000,1500000,1500000,1086320,3000000,561844,1765215,686796,3386144,2175000,2175000,2175000,2175000,1150000,1150000,1150000,1150000,1100000,1100000,1100000,1100000,137191,137191,1444748,1444748,2319081,1319081,1349490,648470,1159350,377448,1250000,364700,257852,1987500,424411,310000,1752844,2744074,1409074,1341849,1292325,145578,1176412,950000,900000,1091904,467351,1376,21000,261010,85369,0,348652,691365,3723812,1398549,2095352,1862503,368221,126608,107000,1036104,3402286,1468054,978703,605657,403771,312786,687214,3000000,500000,500000,3500000,1503218,677240,2051474,374880,393187,2000000,2000000,5500000,300000,300000,200000,200000,1000000,4500000], "related_budget_period_start_quarter":[2,2,2,2,2,2,2,2,2,2,1,2,3,4,1,4,4,1,3,1,2,3,4,4,1,3,1,1,2,2,2,2,2,2,2,2,2,1,2,3,4,1,2,3,4,1,2,3,4,1,2,2,2,2,1,2,4,2,4,2,2,2,2,2,3,4,1,2,3,4,1,2,3,4,1,2,3,4,1,2,1,2,3,4,1,2,3,4,1,2,3,4,1,2,3,4,1,2,1,2,3,4,2,4,2,2,4,1,2,4,1,3,4,1,2,4,2,4,2,2,2,2,2,2,1,2,3,4,1,2,4,2,4,2,4,2,4,2,4,2,4,2,4,2,2,4,1,2,3,4,3,2,4,2,4,3,4,1,2,4,2,4,2,2], "related_budget_period_end_quarter":[1,1,1,1,1,1,1,1,1,1,1,2,3,4,4,3,4,1,4,1,2,4,1,1,1,4,1,1,1,1,1,1,1,1,1,1,1,1,2,3,4,1,2,3,4,1,2,3,4,1,1,1,1,1,1,1,3,1,1,1,1,1,1,2,3,4,1,2,3,4,1,2,3,4,1,2,3,4,1,4,1,2,3,4,1,2,3,4,1,2,3,4,1,2,3,4,1,4,1,3,4,1,3,1,1,3,1,1,3,4,2,3,4,1,3,1,3,1,1,1,1,1,1,4,1,2,3,4,1,3,1,3,1,3,1,3,1,3,1,3,1,3,1,1,3,1,1,2,3,4,1,3,1,3,1,3,4,1,3,1,3,1,1,1], "related_budget_period_start_iso_date":["2016-04-01T00:00:00Z","2017-04-01T00:00:00Z","2018-04-01T00:00:00Z","2019-04-01T00:00:00Z","2020-04-01T00:00:00Z","2021-04-01T00:00:00Z","2022-04-01T00:00:00Z","2023-04-01T00:00:00Z","2024-04-01T00:00:00Z","2025-04-01T00:00:00Z","2019-02-01T00:00:00Z","2019-04-01T00:00:00Z","2019-07-01T00:00:00Z","2019-10-01T00:00:00Z","2020-01-01T00:00:00Z","2020-12-01T00:00:00Z","2021-10-01T00:00:00Z","2022-01-01T00:00:00Z","2023-09-01T00:00:00Z","2024-01-01T00:00:00Z","2024-04-01T00:00:00Z","2024-07-01T00:00:00Z","2024-11-01T00:00:00Z","2021-11-04T00:00:00Z","2022-02-01T00:00:00Z","2021-09-28T00:00:00Z","2022-01-01T00:00:00Z","2017-01-01T00:00:00Z","2017-04-01T00:00:00Z","2018-04-01T00:00:00Z","2019-04-01T00:00:00Z","2020-04-01T00:00:00Z","2021-04-01T00:00:00Z","2022-04-01T00:00:00Z","2023-04-01T00:00:00Z","2024-04-01T00:00:00Z","2025-04-01T00:00:00Z","2024-02-01T00:00:00Z","2024-04-01T00:00:00Z","2024-07-01T00:00:00Z","2024-10-01T00:00:00Z","2025-01-01T00:00:00Z","2025-04-01T00:00:00Z","2025-07-01T00:00:00Z","2025-10-01T00:00:00Z","2026-01-01T00:00:00Z","2026-04-01T00:00:00Z","2026-07-01T00:00:00Z","2026-10-01T00:00:00Z","2027-01-01T00:00:00Z","2024-04-05T00:00:00Z","2025-04-01T00:00:00Z","2026-04-01T00:00:00Z","2027-04-01T00:00:00Z","2017-01-01T00:00:00Z","2017-04-01T00:00:00Z","2017-10-30T00:00:00Z","2018-04-01T00:00:00Z","2018-10-01T00:00:00Z","2019-04-01T00:00:00Z","2020-04-01T00:00:00Z","2021-04-01T00:00:00Z","2022-04-01T00:00:00Z","2018-05-16T00:00:00Z","2018-07-01T00:00:00Z","2018-10-01T00:00:00Z","2019-01-01T00:00:00Z","2019-04-01T00:00:00Z","2019-07-01T00:00:00Z","2019-10-01T00:00:00Z","2020-01-01T00:00:00Z","2020-04-01T00:00:00Z","2020-07-01T00:00:00Z","2020-10-01T00:00:00Z","2021-01-01T00:00:00Z","2021-04-01T00:00:00Z","2021-07-01T00:00:00Z","2021-10-01T00:00:00Z","2022-01-01T00:00:00Z","2022-04-01T00:00:00Z","2023-01-01T00:00:00Z","2023-04-01T00:00:00Z","2023-07-01T00:00:00Z","2023-10-01T00:00:00Z","2024-01-01T00:00:00Z","2024-04-01T00:00:00Z","2024-07-01T00:00:00Z","2024-10-01T00:00:00Z","2025-01-01T00:00:00Z","2025-04-01T00:00:00Z","2025-07-01T00:00:00Z","2025-10-01T00:00:00Z","2026-01-01T00:00:00Z","2026-04-01T00:00:00Z","2026-07-01T00:00:00Z","2026-10-01T00:00:00Z","2027-01-01T00:00:00Z","2018-06-14T00:00:00Z","2019-01-01T00:00:00Z","2019-04-01T00:00:00Z","2019-08-01T00:00:00Z","2019-12-01T00:00:00Z","2020-04-01T00:00:00Z","2020-10-01T00:00:00Z","2021-04-01T00:00:00Z","2022-04-01T00:00:00Z","2022-10-01T00:00:00Z","2023-03-01T00:00:00Z","2023-04-01T00:00:00Z","2023-10-01T00:00:00Z","2024-03-01T00:00:00Z","2024-07-01T00:00:00Z","2024-10-01T00:00:00Z","2025-01-01T00:00:00Z","2025-04-01T00:00:00Z","2025-10-01T00:00:00Z","2026-04-01T00:00:00Z","2026-10-01T00:00:00Z","2018-04-01T00:00:00Z","2019-04-01T00:00:00Z","2020-04-01T00:00:00Z","2021-04-01T00:00:00Z","2022-04-01T00:00:00Z","2023-04-01T00:00:00Z","2024-01-01T00:00:00Z","2024-04-01T00:00:00Z","2024-07-01T00:00:00Z","2024-10-01T00:00:00Z","2025-01-01T00:00:00Z","2018-05-16T00:00:00Z","2018-10-01T00:00:00Z","2019-04-01T00:00:00Z","2019-10-01T00:00:00Z","2020-04-01T00:00:00Z","2020-10-01T00:00:00Z","2021-04-01T00:00:00Z","2021-10-01T00:00:00Z","2022-04-01T00:00:00Z","2023-11-01T00:00:00Z","2024-04-01T00:00:00Z","2024-10-01T00:00:00Z","2025-04-01T00:00:00Z","2025-10-01T00:00:00Z","2026-04-01T00:00:00Z","2018-05-22T00:00:00Z","2018-10-01T00:00:00Z","2023-01-01T00:00:00Z","2023-04-01T00:00:00Z","2023-07-01T00:00:00Z","2023-10-01T00:00:00Z","2019-07-01T00:00:00Z","2020-04-01T00:00:00Z","2020-10-01T00:00:00Z","2021-04-01T00:00:00Z","2021-10-01T00:00:00Z","2024-07-01T00:00:00Z","2024-10-01T00:00:00Z","2025-01-01T00:00:00Z","2025-04-01T00:00:00Z","2025-10-01T00:00:00Z","2026-04-01T00:00:00Z","2026-10-01T00:00:00Z","2020-04-01T00:00:00Z","2021-04-01T00:00:00Z"], "related_budget_period_end_iso_date":["2017-03-31T00:00:00Z","2018-03-31T00:00:00Z","2019-03-31T00:00:00Z","2020-03-31T00:00:00Z","2021-03-31T00:00:00Z","2022-03-31T00:00:00Z","2023-03-31T00:00:00Z","2024-03-31T00:00:00Z","2025-03-31T00:00:00Z","2026-03-31T00:00:00Z","2019-03-31T00:00:00Z","2019-06-30T00:00:00Z","2019-09-30T00:00:00Z","2019-12-31T00:00:00Z","2020-11-30T00:00:00Z","2021-09-30T00:00:00Z","2021-12-31T00:00:00Z","2022-03-31T00:00:00Z","2023-12-31T00:00:00Z","2024-03-31T00:00:00Z","2024-06-30T00:00:00Z","2024-10-31T00:00:00Z","2025-03-31T00:00:00Z","2022-01-31T00:00:00Z","2022-03-31T00:00:00Z","2021-12-31T00:00:00Z","2022-03-31T00:00:00Z","2017-03-31T00:00:00Z","2018-03-31T00:00:00Z","2019-03-31T00:00:00Z","2020-03-31T00:00:00Z","2021-03-31T00:00:00Z","2022-03-31T00:00:00Z","2023-03-31T00:00:00Z","2024-03-31T00:00:00Z","2025-03-31T00:00:00Z","2026-03-31T00:00:00Z","2024-03-31T00:00:00Z","2024-06-30T00:00:00Z","2024-09-30T00:00:00Z","2024-12-31T00:00:00Z","2025-03-31T00:00:00Z","2025-06-30T00:00:00Z","2025-09-30T00:00:00Z","2025-12-31T00:00:00Z","2026-03-31T00:00:00Z","2026-06-30T00:00:00Z","2026-09-30T00:00:00Z","2026-12-31T00:00:00Z","2027-03-31T00:00:00Z","2025-03-31T00:00:00Z","2026-03-31T00:00:00Z","2027-03-31T00:00:00Z","2028-03-31T00:00:00Z","2017-03-31T00:00:00Z","2018-03-31T00:00:00Z","2018-09-30T00:00:00Z","2019-03-31T00:00:00Z","2019-03-31T00:00:00Z","2020-03-31T00:00:00Z","2021-03-31T00:00:00Z","2022-03-31T00:00:00Z","2023-03-31T00:00:00Z","2018-06-30T00:00:00Z","2018-09-30T00:00:00Z","2018-12-31T00:00:00Z","2019-03-31T00:00:00Z","2019-06-30T00:00:00Z","2019-09-30T00:00:00Z","2019-12-31T00:00:00Z","2020-03-31T00:00:00Z","2020-06-30T00:00:00Z","2020-09-30T00:00:00Z","2020-12-31T00:00:00Z","2021-03-31T00:00:00Z","2021-06-30T00:00:00Z","2021-09-30T00:00:00Z","2021-12-31T00:00:00Z","2022-03-31T00:00:00Z","2022-12-31T00:00:00Z","2023-03-31T00:00:00Z","2023-06-30T00:00:00Z","2023-09-30T00:00:00Z","2023-12-31T00:00:00Z","2024-03-31T00:00:00Z","2024-06-30T00:00:00Z","2024-09-30T00:00:00Z","2024-12-31T00:00:00Z","2025-03-31T00:00:00Z","2025-06-30T00:00:00Z","2025-09-30T00:00:00Z","2025-12-31T00:00:00Z","2026-03-31T00:00:00Z","2026-06-30T00:00:00Z","2026-09-30T00:00:00Z","2026-12-31T00:00:00Z","2027-03-31T00:00:00Z","2018-12-31T00:00:00Z","2019-03-31T00:00:00Z","2019-07-31T00:00:00Z","2019-11-30T00:00:00Z","2020-03-31T00:00:00Z","2020-09-30T00:00:00Z","2021-03-31T00:00:00Z","2022-03-31T00:00:00Z","2022-09-30T00:00:00Z","2023-03-31T00:00:00Z","2024-02-29T00:00:00Z","2023-09-30T00:00:00Z","2023-12-31T00:00:00Z","2024-06-30T00:00:00Z","2024-09-30T00:00:00Z","2024-12-31T00:00:00Z","2025-03-31T00:00:00Z","2025-09-30T00:00:00Z","2026-03-31T00:00:00Z","2026-09-30T00:00:00Z","2027-03-31T00:00:00Z","2019-03-31T00:00:00Z","2020-03-31T00:00:00Z","2021-03-31T00:00:00Z","2022-03-31T00:00:00Z","2023-03-31T00:00:00Z","2023-12-31T00:00:00Z","2024-03-31T00:00:00Z","2024-06-30T00:00:00Z","2024-09-30T00:00:00Z","2024-12-31T00:00:00Z","2025-03-31T00:00:00Z","2018-09-30T00:00:00Z","2019-03-31T00:00:00Z","2019-09-30T00:00:00Z","2020-03-31T00:00:00Z","2020-09-30T00:00:00Z","2021-03-31T00:00:00Z","2021-09-30T00:00:00Z","2022-03-31T00:00:00Z","2022-09-30T00:00:00Z","2024-03-31T00:00:00Z","2024-09-30T00:00:00Z","2025-03-31T00:00:00Z","2025-09-30T00:00:00Z","2026-03-31T00:00:00Z","2027-03-31T00:00:00Z","2018-09-30T00:00:00Z","2019-03-31T00:00:00Z","2023-03-31T00:00:00Z","2023-06-30T00:00:00Z","2023-09-30T00:00:00Z","2023-12-31T00:00:00Z","2020-03-31T00:00:00Z","2020-09-30T00:00:00Z","2021-03-31T00:00:00Z","2021-09-30T00:00:00Z","2022-03-31T00:00:00Z","2024-09-30T00:00:00Z","2024-12-31T00:00:00Z","2025-03-31T00:00:00Z","2025-09-30T00:00:00Z","2026-03-31T00:00:00Z","2026-09-30T00:00:00Z","2027-03-31T00:00:00Z","2021-03-31T00:00:00Z","2022-03-31T00:00:00Z"], "id":"ef05c19d-90cb-4a25-8f1b-d31040f0dffa", "related_activity_context":"ID: GB-GOV-10-GAMRIF-C-CAMP\nTitle: Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Nurturing breakthrough technologies to solve the global grand challenges of Antimicrobial Resistance (AMR) in the Environment\nDescription: This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This project is delivered in partnership with the Centre for Cellular and Molecular Platforms (C-CAMP) to nurture promising technologies that can solve the global challenges of AMR in the environment. A national and international call for applications (‘AMR Challenge’) will identify innovative solutions addressing prioritised AMR challenges in the environment for the benefit of LMICs. The Challenge will be specific for AMR in the environment with impact across the One Health* domains of human, animal and the environment. The India AMR Innovation Hub’s large stakeholder network may be leveraged to advance Challenge-funded innovations. (*One Health is an integrated, unifying approach that aims to sustainably balance and optimise the health of people, animals and ecosystems. It recognises that the health of humans, domestic and wild animals, plants, and the wider environment (including ecosystems) are closely linked and interdependent.)\n \n ID: GB-GOV-10-GAMRIF\nTitle: Global Antimicrobial Resistance Innovation Fund (GAMRIF)\nDescription: The Global Antimicrobial Resistance Innovation Fund (GAMRIF) is an Official Development Assistance (ODA) funded UKaid programme from the Department of Health and Social Care (DHSC). It supports high-quality research and development (R&D) around the world to reduce the threat of antimicrobial resistance (AMR) in humans, animals, and the environment for the benefit of people in low- and middle-income countries (LMICs), focussing on product development (such as therapeutics, alternatives, vaccines, diagnostics and beyond). GAMRIF delivers through bilateral partnerships, global initiatives, and product development partnerships (PDPs) to establish international research partnerships with industry, academia, and governments. This approach enables it to collaborate with, and leverage additional funding from, other global donors to develop innovative One Health* solutions to tackle AMR in LMICs and increase the availability of context-specific, accessible, and affordable innovations for LMICs. (*One Health is an integrated, unifying approach that aims to sustainably balance and optimise the health of people, animals and ecosystems. It recognises that the health of humans, domestic and wild animals, plants, and the wider environment (including ecosystems) are closely linked and interdependent.)\n \n ID: GB-GOV-10-GAMRIF-BACTIVAC\nTitle: Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Vaccine Innovation with the Bacterial Vaccinology Network (BactiVac)\nDescription: This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF). GAMRIF funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This project is delivered in partnership with the Bacterial Vaccinology Network (BactiVac) to support the development of vaccines for antimicrobial resistance (AMR) in humans and animals. BactiVac is one of five networks that are supported by the Global Challenges Research Fund (GCRF) Networks in Vaccines Research and Development which is co-funded by the UK Medical Research Council (MRC) and the UK Biotechnology and Biological Sciences Research Council (BBSRC). The primary aim of this investment is to accelerate the development of vaccines against bacterial infections, so that antimicrobial use in humans and animals is reduced in LMICs. This investment also supports new, diverse research projects to gain preliminary data and encourage new research partnerships, and allow these collaborations to build a track record, which will allow them to obtain further funding. It is expected that some of these projects will not yield expected research results, yet the dissemination of both positive and negative research outcomes is valuable and expected. Funded projects will undertake early-stage research and development with catalyst pump-priming funding around the world to help drive the development and uptake of vaccines for AMR for the benefit of people in LMICs.\n \n ID: GB-GOV-10-GAMRIF-CHAI\nTitle: Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Developing a market shaping framework for antimicrobial resistance (AMR) interventions in developing countries\nDescription: This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This project is delivered in partnership with the Clinton Health Access Initiative (CHAI), a global health organisation committed to saving lives and reducing the burden of disease in LMICs. It works with partners to strengthen the capabilities of governments and the private sector to create and sustain high-quality health systems that can succeed independently. The programme supports target countries (Kenya, Malawi, India, Laos, Vietnam) to collect data on AMR to inform the identification of large-scale interventions. DHSC invested £645k over a 5-month period into CHAI, with Cornell University supporting in an advisory capacity.\n \n ID: GB-GOV-10-GAMRIF-ICARS\nTitle: Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Tackling Antimicrobial Resistance in Colombia via diagnostic uptake in pig farming\nDescription: This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This project is delivered in partnership with the International Centre for Antimicrobial Resistance Solutions (ICARS), an international organisation created by the Danish government to tackle the barriers to successfully addressing AMR. This multi-funder arrangement offers risk-sharing, the potential to leverage co-funding and benefit from the existing relationships between ICARS and stakeholders in Colombia and wider Latin America (a region where GAMRIF-supported innovations may have significant benefit). DHSC and ICARS are undertaking a pilot partnership which will identify challenges and successes in the uptake of a novel and subsidised diagnostic platform. This will be available to the pig farming industry in Colombia and will support increased diagnosis, therefore reducing inappropriate antimicrobial use. This project is managed on behalf of GAMRIF by ICARS via Porkcolombia with support from the Colombian Ministry of Agriculture and Rural Development, who ICARS already hold an existing relationship with.\n \n ID: GB-GOV-10-GAMRIF-ProgrammeCosts\nTitle: Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Programme Costs\nDescription: This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF). GAMRIF funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. Programme costs support the running of the programme through additional activity, such as events with delivery partners or Monitoring, Evaluation and Learning (MEL) resources.\n \n ID: GB-GOV-10-GAMRIF-WP11-CMM\nTitle: Global Antimicrobial Resistance Innovation Fund (GAMRIF) - FAILSAFE (Fungal AMR Innovations for low- and middle-income countries): Solutions and Access for Everyone\nDescription: This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. Delivered in partnership with the University of Exeter, this is a pioneering initiative which aims to address the urgent and underfunded challenge of fungal antimicrobial resistance (fAMR). It will foster global research and development to create impactful products and solutions for fAMR across the One Health* spectrum by providing funding for small to large scale research projects in basic and clinical medical mycology, focusing on LMICs, where the effects of fAMR are particularly severe. (*One Health is an integrated, unifying approach that aims to sustainably balance and optimise the health of people, animals and ecosystems. It recognises that the health of humans, domestic and wild animals, plants, and the wider environment (including ecosystems) are closely linked and interdependent.)\n \n ID: GB-GOV-10-GAMRIF-WP12-MHRA\nTitle: Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Global Health Security and Medicines and Healthcare products Regulatory Agency (MHRA)\nDescription: This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This partnership with the Medicines and Healthcare products Regulatory Agency (MHRA) aims to provide regulatory and policy support to GAMRIF funded activities globally by: (1) Providing early-stage regulatory advice through existing innovation accelerator; (2) Underpinning regulatory scientific research to establish the scientific framework for assuring the quality of products; and (3) Providing assistance on the preparation of calibrants and running controls required to measure medicinal products’ critical quality attributes. MHRA will develop non-mandatory regulatory guidance that draws on national guidelines and advice from national regulators, maximising the likelihood that innovative products developed within GAMRIF funded portfolios secure regulatory approval in both LMICs and high-income countries (HICs). This project was not put out to an open, competitive tender process because MHRA is an executive agency of DHSC and therefore exempt from the tender process as it is within DHSC’s body of expertise.\n \n ID: GB-GOV-10-GAMRIF-WP1-UK-CHINA\nTitle: Global Antimicrobial Resistance Innovation Fund (GAMRIF) - UK-China: Innovation and Collaboration to Tackle Antimicrobial Resistance\nDescription: This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF). GAMRIF funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. The UK-China research competition supports new innovations to address AMR in both humans and animals, which both constitute a significant threat to human health. Successful projects are a partnership between UK companies / research organisations and Chinese companies /research organisations, with outputs benefitting people in other LMICs. Partnerships will support novel research projects to develop the use of cutting-edge solutions to tackle the critical issues of AMR in humans and animals. This includes solutions that will: (1) Explore opportunities for the treatment and/or prevention of infectious diseases in humans and animals; (2) Advance the discovery of new agents, including small molecule drugs, vaccines, antibodies and other biological products; (3) Identify new agents that increase feed energy conversion in livestock without using antibiotics or hormones; (4) Use modelling and clinical studies to maximise the clinical utility of current antibiotics; and (5) Improve diagnostic capabilities for the diagnosis, treatment selection and surveillance of bacterial infections and antibacterial resistance. This project was not put out to an open, competitive tender process because, as a non-departmental public body of the UK government, Innovate UK is uniquely positioned to manage research calls.\n \n ID: GB-GOV-10-GAMRIF-WP2-CARB-X\nTitle: Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Accelerating Antibacterial Innovation with Combating Antibiotic Resistant Bacteria Accelerator (CARB-X)\nDescription: This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This project is delivered in partnership with Boston University’s Combating Antibiotic Resistant Bacteria Accelerator (CARB-X), a non-profit, multi-donor international partnership that supports innovative early product research and development focused on the most dangerous drug-resistant bacteria. This partnership will invest in high-value, innovative research to accelerate the development of products to reduce the harm to human health, welfare and economic growth from drug-resistant infections, up to and including Phase I. The programme will focus on prevention (including vaccines) and alternatives to antibiotics for humans as primarily and directly relevant to people in LMICs.\n \n ID: GB-GOV-10-GAMRIF-WP3-InnoVet-AMR\nTitle: Global Antimicrobial Resistance Innovation Fund (GAMRIF) - InnoVet AMR: Innovative Veterinary Solutions for Antimicrobial Resistance (AMR) with the International Development Research Centre (IDRC)\nDescription: This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This project is delivered in partnership with the International Development Research Centre (IDRC) and aims to reduce the emerging risk that antimicrobial resistance (AMR) in animals poses to global health and food security. InnoVet-AMR will fund research to develop new animal vaccines and other innovations to fight AMR in livestock (swine and poultry) and aquaculture production, particularly in LMICs. Through InnoVet-AMR, DHSC and IDRC aim to achieve two main objectives: (1) Support research that will identify innovative veterinary solutions, including vaccines and alternative solutions, to reduce the use of antimicrobials in livestock and aquaculture operations in LMICs; and (2) Build effective partnerships to better coordinate discovery, development and sustainable delivery of affordable innovative veterinary solutions to reduce the use of antimicrobials in livestock and aquaculture operations in LMICs. As part of the InnoVet-AMR programme, GAMRIF has also allocated additional funding to a partnership with the International Centre for Antimicrobial Resistance Solutions (ICARS). This complimentary research activity will support scoping and research projects focused on climate change, gender and equity in AMR mitigation.\n \n ID: GB-GOV-10-GAMRIF-WP4-UK-Argentina\nTitle: Global Antimicrobial Resistance Innovation Fund (GAMRIF) - UK-Argentina: Tools to Tackle Antimicrobial Resistance (AMR) in the Environment\nDescription: This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. This project is delivered as a bilateral partnership with Argentina to support research to tackle AMR in agriculture and the impact on the environment. Successful projects are a partnership of UK companies and research organisations with Argentinian companies and research organisations. The competition and partnership will be delivered in the UK by the Biotechnology and Biological Sciences Research Council (BBSRC) in partnership with the Natural Environment Research Council (NERC), both part of UK Research and Innovation (UKRI). It will be delivered and match-funded, on a resource basis, by the National Scientific and Technical Research Council (CONICET) in Argentina. The aim of this partnership is to generate new knowledge and provide a deeper evidence base to reduce the impact of drivers of AMR in the environment from agricultural sources in the contexts of Argentina and LMICs. This includes research to develop theoretical frameworks for surveillance and reporting on AMR and antibiotics, and research to develop strategies for manure, slurry and waste management. Projects are also required to produce outputs that translate research into policy, such as policy briefings or best practice position papers for LMICs.\n \n ID: GB-GOV-10-GAMRIF-WP5-FIND\nTitle: Global Antimicrobial Resistance Innovation Fund (GAMRIF) - Innovation in Antimicrobial Resistance (AMR) Diagnostic Tools with the Foundation for Innovative New Diagnostics (FIND)\nDescription: This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. The project is delivered in partnership with the Foundation for Innovative New Diagnostics (FIND), a global non-profit product development partnership that aims to develop, evaluate and deliver high-quality affordable diagnostic tests for poverty-related diseases. Funding through GAMRIF will support FIND’s work to enhance the impact of diagnostic tools for AMR, improving AMR surveillance and antibiotic stewardship. This work has two areas of focus: (1) To develop technological methods to connect data from patient testing and health provider consultations to larger data systems, such as national and international AMR surveillance programmes. This will lead to improved antibiotic use and AMR surveillance through increased access to data; and (2) To develop new diagnostic technologies for drug-resistant gonorrhoea, which will enable improved diagnosis and therefore use of new antibiotics.\n \n ID: GB-GOV-10-GAMRIF-WP6-GARDP\nTitle: Global Antimicrobial Resistance Innovation Fund (GAMRIF) - New Antibiotic for Drug-Resistant Gonorrhoea with the Global Antibiotic Research and Development Partnership (GARDP) - Phase 1b\nDescription: This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. The project is delivered in partnership with the Global Antibiotic Research and Development Partnership (GARDP), a non-profit product development partnership, hosted by the Drugs for Neglected Diseases Initiative (DNDi) and founded in association with the World Health Organization (WHO). It is a research and development initiative addressing global public health needs by developing, delivering and assuring sustainable access to new or improved antibiotic treatments. GAMRIF funding will support GARDP’s programme on sexually transmitted infections (STIs), specifically focusing on the development of a new antibiotic for drug-resistant gonorrhoea. The aim of this project is to fund and support the development of new treatments that address the threat of drug-resistant gonorrhoea in LMICs. Objectives of the funded activity are to: (1) Develop a new affordable treatment for gonorrhoea, that works on multi-drug-resistant cases (trials completed and registration started by 2022); and (2) Support the integration of the new treatments into the current STI management framework by investigating possible antibiotic combinations by 2023.\n \n ID: GB-GOV-10-GAMRIF-WP6-GARDP-2\nTitle: Global Antimicrobial Resistance Innovation Fund (GAMRIF) - New Antibiotic Treatments with the Global Antibiotic Research and Development Partnership (GARDP) - Phase II\nDescription: This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. The project is delivered in partnership with the Global Antibiotic Research and Development Partnership (GARDP), a non-profit product development partnership, hosted by the Drugs for Neglected Diseases Initiative (DNDi) and founded in association with the World Health Organization (WHO). It is a research and development initiative addressing global public health needs by developing, delivering and assuring sustainable access to new or improved antibiotic treatments. GAMRIF funding will support GARDP to develop and deliver new treatments for drug-resistant infections across the following three programmes: (1) Serious bacterial infections (SBIs); (2) Children’s antibiotics (neonatal sepsis and paediatric development); and (3) Sexually transmitted infections (STIs), including the novel antibiotic, zoliflodacin, for drug-resistant gonorrhoea.\n \n ID: GB-GOV-10-GAMRIF-WP6-GARDP-2019-2022\nTitle: Global Antimicrobial Resistance Innovation Fund (GAMRIF) - New Antibiotic for Drug-Resistant Gonorrhoea with the Global Antibiotic Research and Development Partnership (GARDP) - Phase 1a\nDescription: This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. The project is delivered in partnership with the Global Antibiotic Research and Development Partnership (GARDP), a non-profit product development partnership, hosted by the Drugs for Neglected Diseases Initiative (DNDi) and founded in association with the World Health Organization (WHO). It is a research and development initiative addressing global public health needs by developing, delivering and assuring sustainable access to new or improved antibiotic treatments. GAMRIF funding will support GARDP’s programme on sexually transmitted infections (STIs), specifically focusing on the development of a new antibiotic for drug-resistant gonorrhoea. The aim of this project is to fund and support the development of new treatments that address the threat of drug-resistant gonorrhoea in LMICs. Objectives of the funded activity are to: (1) Develop a new affordable treatment for gonorrhoea, that works on multi-drug-resistant cases (trials completed and registration started by 2022); and (2) Support the integration of the new treatments into the current STI management framework by investigating possible antibiotic combinations by 2023; and (3) Support the development of a stewardship and access strategy for LMICs for the new antibiotic treatment.\n \n ID: GB-GOV-10-GAMRIF-WP6-GARDP-3\nTitle: Global Antimicrobial Resistance Innovation Fund (GAMRIF) - New Antibiotic Treatments with the Global Antibiotic Research and Development Partnership (GARDP) - Phase III\nDescription: This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. The project is delivered in partnership with the Global Antibiotic Research and Development Partnership (GARDP), a non-profit product development partnership, hosted by the Drugs for Neglected Diseases Initiative (DNDi) and founded in association with the World Health Organization (WHO). It is a research and development initiative addressing global public health needs by developing, delivering and assuring sustainable access to new or improved antibiotic treatments. GAMRIF funding will support GARDP to develop and deliver new treatments for drug-resistant infections across the following three programmes: (1) Serious bacterial infections (SBIs); (2) Children’s antibiotics (neonatal sepsis and paediatric development); and (3) Sexually transmitted infections (STIs).\n \n ID: GB-GOV-10-GAMRIF-WP6-GARDP-CORE\nTitle: Global Antimicrobial Resistance Innovation Fund (GAMRIF) and the Global Antibiotic Research and Development Partnership (GARDP) - Phase 1 - Core Funding\nDescription: This is an Official Development Assistance (ODA) funded UKaid project from the Department of Health and Social Care (DHSC)’s Global Antimicrobial Resistance Innovation Fund (GAMRIF) which funds research and development to fight antimicrobial resistance (AMR) in low- and middle-income countries (LMICs) where the burden of drug-resistant infection is greater. The Global Antibiotic Research and Development Partnership (GARDP) is a non-profit product development partnership, hosted by the Drugs for Neglected Diseases Initiative (DNDi) and founded in association with the World Health Organization (WHO). It is a research and development initiative addressing global public health needs by developing, delivering and assuring sustainable access to new or improved antibiotic treatments. GAMRIF funding will provide unearmarked, core funding to GARDP to support the development and delivery of new treatments for drug-resistant infections that pose the greatest threat to health, with the primary focus to enable distribution of treatments to people in LMICs.\n", "_version_":1862221872352985088 }] } }